Antisense IGF-I for Hepatocellular Carcinoma

互联网2014-02-13

792

Antisense gene therapy involves the selective inhibition of expression or function of disease-causing genes by treatment with an antisense molecules (RNA or oligodeoxynucleotides) complementary to its target nucleic acids, usually to some specific mRNA molecules or mRNA precursor molecules, at a specific site (1 ,2 ) (see also Note 1 ).

相关产品推荐

Bpifb1/Bpifb1蛋白Recombinant Mouse BPI fold-containing family B member 1 (Bpifb1)重组蛋白Long palate, lung and nasal epithelium carcinoma-associated protein 1蛋白

￥1536

IGF1R重组蛋白|Recombinant Human IGF1R / CD221 Protein (His Tag)

￥2570

Recombinant-Human-Uncharacterized-protein-ATPAF1-AS1ATPAF1-AS1Uncharacterized protein ATPAF1-AS1 Alternative name(s): ATPAF1 antisense RNA 1 ATPAF1 antisense gene protein 1

￥10612

MAGEC2/MAGEC2蛋白Recombinant Human Melanoma-associated antigen C2 (MAGEC2)重组蛋白(Cancer/testis antigen 10)(CT10)(Hepatocellular carcinoma-associated antigen 587)(MAGE-C2 antigen)(MAGE-E1 antigen)蛋白

￥1836

TACSTD2/TACSTD2蛋白Recombinant Human Tumor-associated calcium signal transducer 2 (TACSTD2) (Active)重组蛋白(Cell surface glycoprotein Trop-2)(Membrane component chromosome 1 surface marker 1)(Pancreatic carcinoma marker protein GA733-1)蛋白

￥1368

关于丁香通

公司信息

个人用户

企业机构

无忧采购轻松科研

提问

扫一扫

实验小助手

扫码领资料

反馈

TOP

打开小程序